VML 252

Drug Profile

VML 252

Latest Information Update: 03 Oct 2003

Price : $50

At a glance

  • Originator BTG; Kings College London
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hyperphosphataemia

Most Recent Events

  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
  • 26 Jan 2001 Vernalis Group is seeking potential partners for development and commercialisation of VML 252 (www.vernalis.com)
  • 13 Jan 1999 Discontinued-II for Hyperphosphataemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top